Prostap DCS at a glance

Prostap DCS (leuprorelin):

• Has treated over 24 million patients globally since 1996, across all indications¹
• benefits from 30 years of experience of leuprorelin^2,3
• has been shown to provide long-term survival for prostate cancer patients, when combined with radiotherapy⁴
• has a well-established tolerability: majority of adverse events are related to androgen deprivation; most common events are hot flushes, increased sweating and decreased libido^4-8
• includes a device which is easy to administer^7,8

• helps protect HCPs from needle stick injuries. Prostap DCS is fitted with a safety device that complies with the latest EU sharps directive and UK legislation^7,8,10
• can be used whenever and LHRH agonist is required for the management of prostate cancer, including neo-adjuvant to radiotherapy^4,7,8,11

*Men receiving LHRH agonists are at increased risk of developing diabetes and cardiovascular disease. Patients at high risk should appropriately monitored and managed according to current clinical practice. For a full list of adverse events, please refer to the summary of product characteristics.^7,8

About Prostap DCS^7,8

• Dual Chamber Syringe (DCS) system delivering leuprorelin^7,8

Therapeutic indications^7,8

Prostate cancer

• Metastatic prostate cancer
• Locally advanced prostate cancer, as an alternative to surgical castration
• As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
• As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
• As neo-adjuvant treatment prior to radiotherapy in patients with hish-risk localised or locally advanced prostate cancer

Endometriosis

• Management of endometriosis, including pain relief and reduction of endometriotic lesions
• Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection
• Preoperative management of uterine fibroids to reduce their size and associated bleeding

Central precocious puberty

• Central precocious puberty in girls under 9 years of age and boys under 10 years of age

Administration overview

Intramuscular (IM) or subcutaneous (SC) administration available, depending on indication and dose

Dosage form

Released from micro particles that are 20µm in diameter

Needle size

Fine gauge needle

Image not to scale

Dosing – Prostap SR DCS⁷

Dosing – Prostap 3 DCS⁸